EGTX Egetis Therapeutics AB (publ)

1.095USD11.12 SEK · STO-0.18%Mkt Cap: 508.92M USDP/E: —

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for t…

Institutional holders1 on file

Key Statistics

Company
Market Cap508.92M USD
Enterprise Value489.96M USD
Revenue (TTM)6.89M USD
Gross Profit1.22M USD
Net Income (TTM)-33.71M USD
Revenue/Share0.02 USD
Last Price1.095 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees61
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0003815604
Valuation
P/E (Trailing)—
P/E (Forward)92.67
PEG—
EV/EBITDA-11.32
EV/Revenue71.11
P/S73.86
P/B15.19
EPS (TTM)-0.11 USD
EPS (Forward)0.01 USD
52W Range
0.356899% of range1.102
52W High1.102 USD
52W Low0.3568 USD
Profitability
Gross Margin19.87%
Oper. Margin-639.71%
EBITDA Margin0.00%
Profit Margin-548.88%
ROE-101.15%
ROA-53.59%
ROIC-154.57%
ROCE-82.87%
Growth
Revenue Growth23.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.28M USD
CapEx (TTM)147.64K USD
FCF Margin-284.73%
FCF Yield-3.85%
Net Debt-18.96M USD
Net Debt/EBITDA0.44
Net Debt/FCF—
Balance Sheet
Debt/Equity0.27
Current Ratio1.02
Quick Ratio0.99
Book Value/Sh0.07 USD
Cash/Share0.06 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.104 USD
Upside (mean)+0.8%
Target Range0.4232 USD – 1.772 USD
0.4232+0.8% to mean1.772
# Analysts4
Ownership
Shares Out.464.97M
Float240.08M
Insiders23.39%
Institutions55.08%
Technical
SMA 500.9257 (+18.2%)
SMA 2000.6763 (+61.8%)
Beta0.81
S&P 52W Chg12.00%
Avg Vol (30d)3.49M
Avg Vol (10d)6.75M
Technical Indicators
RSI (14)70.1
MACD0.5204
MACD Signal0.5351
MACD Hist.-0.0147
BB Upper1.179 USD
BB Middle1.039 USD
BB Lower0.8993 USD
BB Width26.89%
ATR (14)0.0267 USD
Vol Ratio (20d)0.29x

About Egetis Therapeutics (STO: EGTX)

›

Egetis Therapeutics (STO: EGTX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 61 employees.

The shares were at 11.12 SEK on 19 November 2026, up 79.9% over 52 weeks. Its 52-week range is 3.625 SEK to 11.20 SEK, and it trades at the top of that range.

Its market capitalisation is 5.17B SEK.

Egetis Therapeutics reports return on equity of -101.2% and revenue up 23.0% year over year.

It holds more cash than debt, a net cash position of 192.60M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Hold; their mean price target of 11.21 SEK is 0.8% above the current price. The next earnings report is expected on 25 February 2027.